Table 2.
Predictive factors for worse biochemical control on proportional hazard model
| Factors | N (event) | Univariate | bNED at 7 year,% | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |||
| Age | 216 (22) | 0.944 | 0.880-1.013 | 0.108 | ||||
| Duration of neoadjuvant ADT | 216 (22) | 0.987 | 0.909-1.071 | 0.746 | ||||
| Initial PSA | 216 (22) | 1.006 | 1.002-1.011 | 0.008 | 1.003 | 0.995-1.012 | 0.483 | |
| Gleason score | 0.011 | 0.068 | ||||||
| < 8 | 126 (7) | 1.000 | (reference) | 93.7 | 1.000 | (reference) | ||
| ≥ 8 | 90 (15) | 3.164 | 1.290-7.751 | 79.1 | 2.551 | 0.931-6.993 | ||
| Biopsy positive core rates | 0.007 | 0.141 | ||||||
| < 67% | 148 (8) | 1.000 | (reference) | 93.7 | 1.000 | (reference) | ||
| ≥ 67% | 65 (14) | 4.464 | 1.872-10.63 | 72.9 | 2.336 | 0.753-7.246 | ||
| T stage (2009 AJCC) | 0.003 | 0.605 | ||||||
| T1c-T3a | 178 (13) | 1.000 | (reference) | 91.2 | 1.000 | (reference) | ||
| T3b-T4 | 38 (9) | 3.623 | 1.550-8.474 | 71.4 | 0.759 | 0.266-2.164 | ||
| PSA nadir after radiotherapy | < 0.001 | < 0.001 | ||||||
| ≤ 0.02 ng/ml | 20 (9) | 1.000 | (reference) | 94.1 | 1.000 | (reference) | ||
| > 0.02 ng/ml | 196 (13) | 28.57 | 12.04-66.66 | 22.9 | 26.31 | 10.00-71.42 | ||
HR – hazard ratio, CI – confidence interval, bNED – biochemical no evidence of disease, ADT – androgen deprivation therapy, PSA – prostate specific antigen, AJCC – American Joint Committee on Cancer